Krsnaa Diagnostics Limited (KRSNAA) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Krsnaa Diagnostics Limited ₹583, price ₹555, upside +5.0%, quality 42 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Krsnaa Diagnostics Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
60‑month range ₹355.26 – ₹1,013 · fair‑value band ₹423.68 – ₹741.82 · the ₹554.85 price screens below the ₹582.75 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.
Follow Krsnaa Diagnostics in your weekly email
Every Wednesday you see whether Krsnaa Diagnostics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Krsnaa Diagnostics Limited provides diagnostic services in India. It offers a range radiology services, including computed tomography scans, magnetic resonance imaging, X-rays, and ultrasound and advanced imaging; pathology services, such as laboratory, and home collection and preventive health; and teleradiology and telepathology services.
Show more
Krsnaa Diagnostics Limited provides diagnostic services in India. It offers a range radiology services, including computed tomography scans, magnetic resonance imaging, X-rays, and ultrasound and advanced imaging; pathology services, such as laboratory, and home collection and preventive health; and teleradiology and telepathology services. The company also provides other diagnostics services, such as ophthalmic test, mammography, dental imaging, stress test, dual-energy X-ray absorptiometry scan, and bone mineral density test. It serves individual patients, government clients, corporate clients, hospitals, clinics, private practitioner, and other healthcare providers. Krsnaa Diagnostics Limited was incorporated in 2010 and is based in Pune, India.
Stock analysis
Krsnaa Diagnostics Limited (KRSNAA) currently trades at ₹554.85, while our model-based Fair Value estimate is ₹582.75, so the stock looks roughly fairly valued today (gap 4.8%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹886.47 per share, and 7 of the 16 models we run sit above the ₹554.85 price.
Bear case: the Asset-Based group reads lowest at ₹202.49, and 9 of the 16 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹423.68 (bear) to ₹741.82 (bull), the price of ₹554.85 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Krsnaa Diagnostics Limited reported revenue of ₹7.7B in FY2026 versus ₹4.6B in FY2022, a compound +14.1%/yr. Reported net income was ₹1.0B in FY2026, compounding +10.4%/yr from FY2022.
Key figures
Market cap ₹18.2B (≈ $189M) · P/E ratio 18.7 · P/S ratio 2.45 · EPS (TTM) ₹29.67 · Dividend yield 0.4% · Net margin 13.1% · Return on equity 10.9% · Return on assets (EBIT) 7.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 33% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at 5%, KRSNAA screens cheaper than that median.
Fair Value models
Bear ₹423.68Fair Value ₹582.75Bull ₹741.82
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹14.10 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.57/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+7.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.3%
Start year 2021 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.6%
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−9.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−10.3%
Dividend (yield on the price)0.4%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 16%
2026 sits 60% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Compare Krsnaa Diagnostics Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 134 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score42 · Below median
Fair Value upside+5.0% · Above median
Profitability
Return on equity (TTM)10.9% · Above median
Return on assets5.9% · Top 25%
Net margin (TTM)11.6% · Above median
Operating margin (TTM)12.8% · Above median
Growth and dividend
Revenue growth22.1% · Top 25%
Dividend yield (TTM)0.4% · Below median
Balance sheet
Debt / equity0.45× · Highest 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Krsnaa Diagnostics Limited (KRSNAA) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of ₹582.75 versus a price of ₹554.85, about +5% upside (fairly valued).
What is the fair value of KRSNAA?
Our model-based fair value for Krsnaa Diagnostics Limited is ₹582.75 (as of Oct 2, 2026), built from audited fundamentals. The current price: ₹554.85.
What is the quality score of KRSNAA?
Krsnaa Diagnostics Limited has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Krsnaa Diagnostics Limited (KRSNAA)?
Our model-based price target is the fair value of ₹582.75 (as of Oct 2, 2026) from 16 valuation models. Cautious scenario ₹423.68, optimistic scenario ₹741.82. It is a calculation from audited fundamentals, not an analyst target.
What is the Krsnaa Diagnostics Limited stock forecast for 2026?
Our models put fair value at ₹582.75, about +5% upside versus a price of ₹554.85 (fairly valued). Cautious scenario ₹423.68, optimistic scenario ₹741.82. The calculation is refreshed regularly with new filings.
What is the revenue of Krsnaa Diagnostics Limited (KRSNAA)?
Krsnaa Diagnostics Limited reported trailing-twelve-month revenue of about ₹8.4B (latest available figure, as of Oct 2, 2026).
Does Krsnaa Diagnostics Limited pay a dividend?
Krsnaa Diagnostics Limited currently shows a dividend yield of about 0.36% relative to its recent price (as of Oct 2, 2026).
What is the intrinsic value of Krsnaa Diagnostics Limited (KRSNAA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Krsnaa Diagnostics Limited it is ₹582.75 per share (as of Oct 2, 2026), against a price of ₹554.85. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Krsnaa Diagnostics Limited stock overvalued or undervalued in 2026?
As of Oct 2, 2026, KRSNAA trades below its calculated fair value: price ₹554.85, fair value ₹582.75, a gap of about +5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KRSNAA?
No. The price is what the market pays today (₹554.85); the fair value is what the company's own numbers justify (₹582.75). For Krsnaa Diagnostics Limited the two are ₹27.90 per share apart. That gap is exactly why we show both numbers side by side.
How much is Krsnaa Diagnostics Limited worth?
The market values Krsnaa Diagnostics Limited at about ₹18.2B (market capitalisation, as of Oct 2, 2026). Per share that is ₹554.85; our models calculate a fair value of ₹582.75 per share.
What do the bullish and bearish scenarios say about KRSNAA?
Our models span a range for Krsnaa Diagnostics Limited: cautious scenario ₹423.68, base ₹582.75, optimistic ₹741.82 per share (as of Oct 2, 2026, price ₹554.85). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of KRSNAA?
Krsnaa Diagnostics Limited trades at a price-to-earnings ratio of 18.7 (as of Oct 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹582.75 is built from several models across several years. Other multiples: P/B 1.9, P/S 2.2, EV/EBITDA 7.9.
How solid is the balance sheet of Krsnaa Diagnostics Limited (KRSNAA)?
Balance-sheet figures for Krsnaa Diagnostics Limited (as of Oct 2, 2026): return on equity 10.9%, debt of 0.45 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is KRSNAA from its 52-week high?
Krsnaa Diagnostics Limited trades at ₹554.85, about 33% below its 52-week high of ₹829.37 and 7% above the low of ₹518.38 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹582.75 is for.
Which stocks are comparable to Krsnaa Diagnostics Limited?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Krsnaa Diagnostics Limited stock attractive at the current price?
The data as of Oct 2, 2026: price ₹554.85, calculated fair value ₹582.75 (+5%), Quality Score 42/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of KRSNAA calculated?
We run Krsnaa Diagnostics Limited through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹582.75, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Krsnaa Diagnostics Limited currently trades 5 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Krsnaa Diagnostics Limited (KRSNAA)?
The closing price on Oct 1, 2026 was ₹554.85. Our model-based fair value is ₹582.75, about +5% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Krsnaa Diagnostics Limited right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Krsnaa Diagnostics Limited
How large is the market capitalisation of Krsnaa Diagnostics Limited (KRSNAA)?
The market capitalisation of Krsnaa Diagnostics Limited is ₹18.2B (≈ $189M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Krsnaa Diagnostics Limited (KRSNAA)?
The price-to-sales ratio of Krsnaa Diagnostics Limited is 2.45 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Krsnaa Diagnostics Limited (KRSNAA)?
Earnings per share at Krsnaa Diagnostics Limited are ₹29.67 (price ÷ EPS = P/E 18.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Krsnaa Diagnostics Limited (KRSNAA)?
The dividend yield of Krsnaa Diagnostics Limited is 0.4% (payout 6.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Krsnaa Diagnostics Limited (KRSNAA)?
The net margin of Krsnaa Diagnostics Limited is 13.1% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Krsnaa Diagnostics Limited (KRSNAA)?
The return on equity (ROE) of Krsnaa Diagnostics Limited is 10.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Krsnaa Diagnostics Limited (KRSNAA)?
On an EBIT basis the return on assets of Krsnaa Diagnostics Limited is 7.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Krsnaa Diagnostics Limited (KRSNAA)?
The operating margin of Krsnaa Diagnostics Limited is 12.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Krsnaa Diagnostics Limited (KRSNAA)?
Revenue at Krsnaa Diagnostics Limited is growing +22.1% versus a year earlier (3y avg +16.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Krsnaa Diagnostics Limited (KRSNAA)?
Earnings per share at Krsnaa Diagnostics Limited are growing −19.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Krsnaa Diagnostics Limited (KRSNAA) generate?
The free cash flow of Krsnaa Diagnostics Limited is −₹943M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Krsnaa Diagnostics Limited (KRSNAA) carry?
The net debt of Krsnaa Diagnostics Limited is ₹1.7B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Krsnaa Diagnostics Limited in the live analysis
One click puts Krsnaa Diagnostics Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
